Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
2002 1
2005 1
2006 1
2007 2
2009 4
2011 2
2012 5
2013 7
2014 14
2015 27
2016 35
2017 27
2018 24
2019 27
2020 21
2021 26
2022 33
2023 42
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Results by year

Filters applied: . Clear all
Page 1
Head and neck cancer.
Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Mody MD, et al. Among authors: saba nf. Lancet. 2021 Dec 18;398(10318):2289-2299. doi: 10.1016/S0140-6736(21)01550-6. Epub 2021 Sep 22. Lancet. 2021. PMID: 34562395 Review.
An update on larynx cancer.
Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. Steuer CE, et al. Among authors: saba nf. CA Cancer J Clin. 2017 Jan;67(1):31-50. doi: 10.3322/caac.21386. Epub 2016 Nov 29. CA Cancer J Clin. 2017. PMID: 27898173 Free article. Review.
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Ferris RL, et al. Among authors: saba nf. J Clin Oncol. 2022 Jan 10;40(2):138-149. doi: 10.1200/JCO.21.01752. Epub 2021 Oct 26. J Clin Oncol. 2022. PMID: 34699271 Free PMC article. Clinical Trial.
Management of locally recurrent nasopharyngeal carcinoma.
Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, Suárez C, Vermorken JB, Yom SS, Ferlito A. Lee AWM, et al. Among authors: saba nf. Cancer Treat Rev. 2019 Sep;79:101890. doi: 10.1016/j.ctrv.2019.101890. Epub 2019 Aug 21. Cancer Treat Rev. 2019. PMID: 31470314 Review.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. Among authors: saba nf. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer.
Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, Nasti TH, Griffith CC, Im SJ, Wang X, Shin DM, Carrington M, Chen ZG, Sidney J, Sette A, Saba NF, Wieland A, Ahmed R. Eberhardt CS, et al. Among authors: saba nf. Nature. 2021 Sep;597(7875):279-284. doi: 10.1038/s41586-021-03862-z. Epub 2021 Sep 1. Nature. 2021. PMID: 34471285 Free PMC article.
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Chung CH, et al. Among authors: saba nf. Clin Cancer Res. 2022 Jun 1;28(11):2329-2338. doi: 10.1158/1078-0432.CCR-21-3849. Clin Cancer Res. 2022. PMID: 35344035 Free PMC article. Clinical Trial.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. Among authors: saba nf. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
Defining HPV-specific B cell responses in patients with head and neck cancer.
Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC, Griffith CC, Wang X, Chen ZG, Kissick HT, Saba NF, Ahmed R. Wieland A, et al. Among authors: saba nf. Nature. 2021 Sep;597(7875):274-278. doi: 10.1038/s41586-020-2931-3. Epub 2020 Nov 18. Nature. 2021. PMID: 33208941 Free PMC article.
273 results